Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study

F. Calabresi, P. Marolla, L. Di Lauro, C. G. Curcio, G. Paoletti, A. Lombardi, D. Giannarelli, P. Ballatore, C. M. Foggi, M. Di Palma, R. Stolfi, E. Cortesi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A total of 265 patients with metastatic breast cancer were included in a multicentric randomized clinical study with the FAC with or without lonidamine (LND). Objective clinical responses (CR+PR) were observed in 46.7% of the FAC-treated patients (group A) and in 62.1% of the FAC+LND-treated patients (group B) (p = 0.002). Time to progression was 6.3 versus 9.2 months (p = 0.003) and median survival 17.9 versus 18.7 months (N.S.) but in the postmenopausal subgroup patients the median survival was 14.8 versus 18.9 months (p 0.018) for group A versus B, respectively. Group B patients showed no significant increase of toxicity, except for myalgia (WHO grade ≥2 in 24.8% of the LND-heated patients) and epigastralgia (WHO grade ≥2 in 15.0% of the LND-treated patients). These results demonstrate that LND can potentiate the FAC regimen and suggest the need for further investigations of LND combined with other polychemotherapy regimens in breast cancer.

Original languageEnglish
Pages (from-to)753-760
Number of pages8
JournalInternational Journal of Oncology
Volume4
Issue numberSUPPL.
Publication statusPublished - 1994

Fingerprint

Breast Neoplasms
Therapeutics
Survival
Myalgia
lonidamine
Clinical Studies
Combination Drug Therapy

Keywords

  • advanced breast cancer
  • FAC chemotherapy
  • lonidamine
  • potentiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Calabresi, F., Marolla, P., Di Lauro, L., Curcio, C. G., Paoletti, G., Lombardi, A., ... Cortesi, E. (1994). Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. International Journal of Oncology, 4(SUPPL.), 753-760.

Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. / Calabresi, F.; Marolla, P.; Di Lauro, L.; Curcio, C. G.; Paoletti, G.; Lombardi, A.; Giannarelli, D.; Ballatore, P.; Foggi, C. M.; Di Palma, M.; Stolfi, R.; Cortesi, E.

In: International Journal of Oncology, Vol. 4, No. SUPPL., 1994, p. 753-760.

Research output: Contribution to journalArticle

Calabresi, F, Marolla, P, Di Lauro, L, Curcio, CG, Paoletti, G, Lombardi, A, Giannarelli, D, Ballatore, P, Foggi, CM, Di Palma, M, Stolfi, R & Cortesi, E 1994, 'Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study', International Journal of Oncology, vol. 4, no. SUPPL., pp. 753-760.
Calabresi, F. ; Marolla, P. ; Di Lauro, L. ; Curcio, C. G. ; Paoletti, G. ; Lombardi, A. ; Giannarelli, D. ; Ballatore, P. ; Foggi, C. M. ; Di Palma, M. ; Stolfi, R. ; Cortesi, E. / Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. In: International Journal of Oncology. 1994 ; Vol. 4, No. SUPPL. pp. 753-760.
@article{84d179dc51d646aba33c80bcbb5ba90b,
title = "Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study",
abstract = "A total of 265 patients with metastatic breast cancer were included in a multicentric randomized clinical study with the FAC with or without lonidamine (LND). Objective clinical responses (CR+PR) were observed in 46.7{\%} of the FAC-treated patients (group A) and in 62.1{\%} of the FAC+LND-treated patients (group B) (p = 0.002). Time to progression was 6.3 versus 9.2 months (p = 0.003) and median survival 17.9 versus 18.7 months (N.S.) but in the postmenopausal subgroup patients the median survival was 14.8 versus 18.9 months (p 0.018) for group A versus B, respectively. Group B patients showed no significant increase of toxicity, except for myalgia (WHO grade ≥2 in 24.8{\%} of the LND-heated patients) and epigastralgia (WHO grade ≥2 in 15.0{\%} of the LND-treated patients). These results demonstrate that LND can potentiate the FAC regimen and suggest the need for further investigations of LND combined with other polychemotherapy regimens in breast cancer.",
keywords = "advanced breast cancer, FAC chemotherapy, lonidamine, potentiation",
author = "F. Calabresi and P. Marolla and {Di Lauro}, L. and Curcio, {C. G.} and G. Paoletti and A. Lombardi and D. Giannarelli and P. Ballatore and Foggi, {C. M.} and {Di Palma}, M. and R. Stolfi and E. Cortesi",
year = "1994",
language = "English",
volume = "4",
pages = "753--760",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "SUPPL.",

}

TY - JOUR

T1 - Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study

AU - Calabresi, F.

AU - Marolla, P.

AU - Di Lauro, L.

AU - Curcio, C. G.

AU - Paoletti, G.

AU - Lombardi, A.

AU - Giannarelli, D.

AU - Ballatore, P.

AU - Foggi, C. M.

AU - Di Palma, M.

AU - Stolfi, R.

AU - Cortesi, E.

PY - 1994

Y1 - 1994

N2 - A total of 265 patients with metastatic breast cancer were included in a multicentric randomized clinical study with the FAC with or without lonidamine (LND). Objective clinical responses (CR+PR) were observed in 46.7% of the FAC-treated patients (group A) and in 62.1% of the FAC+LND-treated patients (group B) (p = 0.002). Time to progression was 6.3 versus 9.2 months (p = 0.003) and median survival 17.9 versus 18.7 months (N.S.) but in the postmenopausal subgroup patients the median survival was 14.8 versus 18.9 months (p 0.018) for group A versus B, respectively. Group B patients showed no significant increase of toxicity, except for myalgia (WHO grade ≥2 in 24.8% of the LND-heated patients) and epigastralgia (WHO grade ≥2 in 15.0% of the LND-treated patients). These results demonstrate that LND can potentiate the FAC regimen and suggest the need for further investigations of LND combined with other polychemotherapy regimens in breast cancer.

AB - A total of 265 patients with metastatic breast cancer were included in a multicentric randomized clinical study with the FAC with or without lonidamine (LND). Objective clinical responses (CR+PR) were observed in 46.7% of the FAC-treated patients (group A) and in 62.1% of the FAC+LND-treated patients (group B) (p = 0.002). Time to progression was 6.3 versus 9.2 months (p = 0.003) and median survival 17.9 versus 18.7 months (N.S.) but in the postmenopausal subgroup patients the median survival was 14.8 versus 18.9 months (p 0.018) for group A versus B, respectively. Group B patients showed no significant increase of toxicity, except for myalgia (WHO grade ≥2 in 24.8% of the LND-heated patients) and epigastralgia (WHO grade ≥2 in 15.0% of the LND-treated patients). These results demonstrate that LND can potentiate the FAC regimen and suggest the need for further investigations of LND combined with other polychemotherapy regimens in breast cancer.

KW - advanced breast cancer

KW - FAC chemotherapy

KW - lonidamine

KW - potentiation

UR - http://www.scopus.com/inward/record.url?scp=0028196598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028196598&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028196598

VL - 4

SP - 753

EP - 760

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - SUPPL.

ER -